Infinimmune vs Sightera Biosciences
Infinimmune vs Sightera Biosciences, compared side by side on 15 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Infinimmune is on 60/100 and Sightera Biosciences on 43/100.
Where each one leads
Infinimmune
- our overall score: 60/100 against 43/100
- funding raised: $75.0M against $3.0M
Sightera Biosciences
- agent readiness: 47/100 against 42/100
At a glance
| Measure | Infinimmune | Sightera Biosciences |
|---|---|---|
| What it is | Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms. | AI drug discovery startup that learns directly from patient biology to identify and design novel medicines, focusing on oncology and fibrosis. |
| Category | Biotechnology, Pharmaceuticals, Artificial Intelligence, HealthTech | Biotechnology, Artificial Intelligence, Drug Discovery, Oncology |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Platform |
| Founded | 2017 | 2025 |
| Headquarters | Alameda, United States | Antwerp, Belgium |
| Status | Active | Inactive |
Size, funding and growth
| Measure | Infinimmune | Sightera Biosciences |
|---|---|---|
| Employees | 22 | Not published |
| Total funding | $75.0M | $3.0M |
| Latest round | Series A | Pre-Seed |
| LinkedIn followers | 4,055 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Infinimmune | Sightera Biosciences |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 60/100 | 43/100 |
| Traction | 53/100 | 32/100 |
| Team | 70/100 | 60/100 |
| Search visibility | 23/100 | 16/100 |
| Quality | 68/100 | 48/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (42/100) | D (47/100) |
| Domain ratingLink authority, 0-100 | 20/100 | Not published |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Infinimmune | Sightera Biosciences |
|---|---|---|
| CDN | Cloudflare | Not detected |
| CMS | Webflow | Not detected |
| Analytics | Google Analytics 4 | Not detected |
Infinimmune vs Sightera Biosciences: common questions
Which is better, Infinimmune or Sightera Biosciences?
On our 0-100 score Infinimmune rates higher (60/100 against 43/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 15 data points above: read the rows that match what you are buying for.
How do Infinimmune and Sightera Biosciences compare on the numbers?
Infinimmune leads on our overall score (60/100 against 43/100), funding raised ($75.0M against $3.0M). Sightera Biosciences leads on agent readiness (47/100 against 42/100).
Read the full Infinimmune review and pricing or the Sightera Biosciences review and pricing. You can also browse other Infinimmune alternatives we track.